Logo image of AUTL

AUTOLUS THERAPEUTICS PLC (AUTL) Stock Fundamental Analysis

NASDAQ:AUTL - US05280R1005 - ADR

1.57 USD
-0.04 (-2.48%)
Last: 8/27/2025, 8:00:01 PM
1.5827 USD
+0.01 (+0.81%)
After Hours: 8/27/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AUTL. AUTL was compared to 547 industry peers in the Biotechnology industry. AUTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AUTL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AUTL has reported negative net income.
In the past year AUTL has reported a negative cash flow from operations.
In the past 5 years AUTL always reported negative net income.
AUTL had a negative operating cash flow in each of the past 5 years.
AUTL Yearly Net Income VS EBIT VS OCF VS FCFAUTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

AUTL's Return On Assets of -31.59% is fine compared to the rest of the industry. AUTL outperforms 65.63% of its industry peers.
AUTL has a Return On Equity (-65.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -31.59%
ROE -65.74%
ROIC N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
AUTL Yearly ROA, ROE, ROICAUTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

AUTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AUTL Yearly Profit, Operating, Gross MarginsAUTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The debt/assets ratio for AUTL has been reduced compared to a year ago.
AUTL Yearly Shares OutstandingAUTL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
AUTL Yearly Total Debt VS Total AssetsAUTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.03, we must say that AUTL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.03, AUTL perfoms like the industry average, outperforming 52.10% of the companies in the same industry.
AUTL has a Debt/Equity ratio of 0.71. This is a neutral value indicating AUTL is somewhat dependend on debt financing.
The Debt to Equity ratio of AUTL (0.71) is worse than 74.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z -2.03
ROIC/WACCN/A
WACC8.07%
AUTL Yearly LT Debt VS Equity VS FCFAUTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 8.43 indicates that AUTL has no problem at all paying its short term obligations.
AUTL's Current ratio of 8.43 is fine compared to the rest of the industry. AUTL outperforms 75.69% of its industry peers.
A Quick Ratio of 8.07 indicates that AUTL has no problem at all paying its short term obligations.
AUTL's Quick ratio of 8.07 is fine compared to the rest of the industry. AUTL outperforms 74.22% of its industry peers.
Industry RankSector Rank
Current Ratio 8.43
Quick Ratio 8.07
AUTL Yearly Current Assets VS Current LiabilitesAUTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.35% over the past year.
The Revenue has grown by 496.00% in the past year. This is a very strong growth!
Measured over the past years, AUTL shows a very strong growth in Revenue. The Revenue has been growing by 28.31% on average per year.
EPS 1Y (TTM)27.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 122.11% on average per year.
EPS Next Y-0.83%
EPS Next 2Y8.52%
EPS Next 3Y11.8%
EPS Next 5Y20.6%
Revenue Next Year475.44%
Revenue Next 2Y233.39%
Revenue Next 3Y180.81%
Revenue Next 5Y122.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AUTL Yearly Revenue VS EstimatesAUTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
AUTL Yearly EPS VS EstimatesAUTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AUTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUTL Price Earnings VS Forward Price EarningsAUTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUTL Per share dataAUTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.52%
EPS Next 3Y11.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AUTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL (8/27/2025, 8:00:01 PM)

After market: 1.5827 +0.01 (+0.81%)

1.57

-0.04 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners89.31%
Inst Owner Change-2.84%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap417.84M
Analysts85.88
Price Target9.65 (514.65%)
Short Float %6.63%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.59%
Min EPS beat(2)-1.96%
Max EPS beat(2)25.13%
EPS beat(4)2
Avg EPS beat(4)8.42%
Min EPS beat(4)-41.83%
Max EPS beat(4)52.34%
EPS beat(8)2
Avg EPS beat(8)-47.73%
EPS beat(12)5
Avg EPS beat(12)-30.26%
EPS beat(16)7
Avg EPS beat(16)-22.09%
Revenue beat(2)2
Avg Revenue beat(2)192.72%
Min Revenue beat(2)58.95%
Max Revenue beat(2)326.5%
Revenue beat(4)2
Avg Revenue beat(4)46.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)326.5%
Revenue beat(8)2
Avg Revenue beat(8)-10.6%
Revenue beat(12)5
Avg Revenue beat(12)142.7%
Revenue beat(16)5
Avg Revenue beat(16)97.23%
PT rev (1m)-2.17%
PT rev (3m)-3.57%
EPS NQ rev (1m)-1.24%
EPS NQ rev (3m)6.28%
EPS NY rev (1m)5.7%
EPS NY rev (3m)4.93%
Revenue NQ rev (1m)28.08%
Revenue NQ rev (3m)146.79%
Revenue NY rev (1m)28.55%
Revenue NY rev (3m)70.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.96
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.25
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0.11
BVpS1.3
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.59%
ROE -65.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 565.42%
Cap/Sales 163.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.43
Quick Ratio 8.07
Altman-Z -2.03
F-Score2
WACC8.07%
ROIC/WACCN/A
Cap/Depr(3y)254.9%
Cap/Depr(5y)225.76%
Cap/Sales(3y)387.17%
Cap/Sales(5y)479.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-0.83%
EPS Next 2Y8.52%
EPS Next 3Y11.8%
EPS Next 5Y20.6%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
Revenue Next Year475.44%
Revenue Next 2Y233.39%
Revenue Next 3Y180.81%
Revenue Next 5Y122.11%
EBIT growth 1Y-37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.18%
EBIT Next 3Y9.54%
EBIT Next 5Y24.14%
FCF growth 1Y-118.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.04%
OCF growth 3YN/A
OCF growth 5YN/A